Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>IDEXX Laboratories reported its first-quarter 2025 financial results, revealing a mixed performance with notable areas of strength as well as challenges.</li><li>Overall, IDEXX achieved a 5% organic revenue growth, a figure backed by a 4.5% increase in CAG Diagnostics recurring revenues despite facing a 1.5% headwind from fewer equivalent days.</li><li>The company's veterinary software and diagnostic imaging revenues were particularly strong, showing a 9% organic gain, highlighting robust demand in this segment.</li></ul>

IDEXX Laboratories reported its first-quarter 2025 financial results, revealing a mixed performance with notable areas of strength as well as challenges.Overall, IDEXX achieved a 5% organic revenue growth, a figure backed by a 4.5% increase in CAG Diagnostics recurring revenues despite facing a 1.5% headwind from fewer equivalent days.The company's veterinary software and diagnostic imaging revenues were particularly strong, showing a 9% organic gain, highlighting robust demand in this segment.

IDEXX Laboratories Is Defying Global Economic Shocks—How Is It Thriving Amid Tariff Turbulence & Market Volatility?

Independent in-depth research from Finimize, Finimize

Finimize Research

Independent in-depth research from Finimize

Finimize

Finimize is the #1 information platform for modern investors. We empower people to become smarter investors with bitesize insights from world-class analysts. 1 million+ strong community, 250 partners.

<ul>
<li>IDEXX Laboratories,  a $35 billion company, is a global leader in veterinary diagnostics, selling and developing the tools that help vets diagnose and treat animals.</li>
<li>IDEXX operates a highly recurring, subscription-like business model, particularly in its Companion Animal Group (CAG), which accounts for over 90% of its revenue.</li>
<li>IDEXX is a cash-generating, high-return compounder at the center of a booming industry and stock looks undervalued right now.</li>
</ul>


IDEXX Laboratories,  a $35 billion company, is a global leader in veterinary diagnostics, selling and developing the tools that help vets diagnose and treat animals.
IDEXX operates a highly recurring, subscription-like business model, particularly in its Companion Animal Group (CAG), which accounts for over 90% of its revenue.
IDEXX is a cash-generating, high-return compounder at the center of a booming industry and stock looks undervalued right now.


IDEXX: Pet Healthcare Could Be An Investor's Best Friend

<ul><li>IDEXX Laboratories, a global leader in veterinary diagnostics, software, and water quality products, closed out 2024 with a solid performance, surpassing expectations and setting a strong foundation for 2025.</li><li>The company reported a 6% organic revenue increase in Q4 2024, driven by a 7% rise in its core Companion Animal Group (CAG) Diagnostic recurring revenues.</li><li>Operating profits grew 7% as reported, and 8% on a comparable basis, supported by favorable gross margin gains.</li></ul>

IDEXX Laboratories, a global leader in veterinary diagnostics, software, and water quality products, closed out 2024 with a solid performance, surpassing expectations and setting a strong foundation for 2025.The company reported a 6% organic revenue increase in Q4 2024, driven by a 7% rise in its core Companion Animal Group (CAG) Diagnostic recurring revenues.Operating profits grew 7% as reported, and 8% on a comparable basis, supported by favorable gross margin gains.

IDEXX Laboratories: Executing International Expansion To Capitalize On Its Competitive Edge Across Global Veterinary Markets!

Mostly Borrowed Ideas Deep Dives, MBI Deep Dives

MBI Deep Dives

Mostly Borrowed Ideas Deep Dives

MBI is the abbreviation for “Mostly Borrowed Ideas”. Why “Mostly Borrowed Ideas?” As a generalist, I do not have a background in any particular sector. I enjoy navigating across industries, businesses, and countries to learn, understand, and connect the dots. In any case, most ideas and innovations are incremental in nature. Very few of us are smart enough to come up with truly original or groundbreaking ideas. I am Abdullah Al-Rezwan. I was born and brought up in Bangladesh. I went to University of Dhaka for my undergrad and majored in Finance. After working three and half years in Equity Research (Sell-side) covering Financial Sector in Bangladesh, I left Bangladesh to pursue my MBA in the US. I graduated within top 10% of the class from Cornell University's two-year MBA program and worked on the buy-side following my graduation. During my time at Cornell, I won two stock pitch competitions and also became finalists in four other competitions. I thoroughly enjoyed my stint as a generalist in the US large cap team at Madison Investments and covered a wide range of companies from UnitedHealth to Amazon and Boeing before US immigration reality paused my career in investment management. As my work authorization expired, I moved to Canada in January, 2021. Then in early 2022, I was able to return to the US.

<ul><li>Like most good comedy bit, it is funny probably because there is an element of truth to it. As a society, we are increasingly humanizing our pets.</li><li>When we look at our pets, we increasingly don’t just consider them our mere properties, rather we sense a much deeper bond to a sentient beings.</li><li>Former Petco CEO Ron Coughlin provided some numbers to contextualize society’s growing sense of devotion to our pets:“Pet parents don’t want to be called pet owners. Seventy-seven percent say they want to be called pet parents, and 60 percent say they love spoiling their pets.”</li></ul>

Like most good comedy bit, it is funny probably because there is an element of truth to it. As a society, we are increasingly humanizing our pets.When we look at our pets, we increasingly don’t just consider them our mere properties, rather we sense a much deeper bond to a sentient beings.Former Petco CEO Ron Coughlin provided some numbers to contextualize society’s growing sense of devotion to our pets:“Pet parents don’t want to be called pet owners. Seventy-seven percent say they want to be called pet parents, and 60 percent say they love spoiling their pets.”

IDEXX: Leading the Humanization of Pet Care Through Diagnostics

<ul><li>IDEXX Laboratories, a prominent player in the diagnostics and veterinary healthcare sector, demonstrated a mixed performance in its latest earnings report for the third quarter of 2024.</li><li>The financial outcomes and the company's strategic movements indicate both strengths and challenges that prospective investors should consider.</li><li>Starting with the positives, IDEXX reported a 6% organic revenue growth, driven significantly by a 7% increase in Companion Animal Group (CAG) Diagnostic recurring revenues and a robust 13% growth in the water business.</li></ul>

IDEXX Laboratories, a prominent player in the diagnostics and veterinary healthcare sector, demonstrated a mixed performance in its latest earnings report for the third quarter of 2024.The financial outcomes and the company's strategic movements indicate both strengths and challenges that prospective investors should consider.Starting with the positives, IDEXX reported a 6% organic revenue growth, driven significantly by a 7% increase in Companion Animal Group (CAG) Diagnostic recurring revenues and a robust 13% growth in the water business.

IDEXX Labs: Will Its Enhanced Diagnostic Capabilities & Innovation Bring A Shift In The Competitive Dynamics? - Major Drivers

United States

IDEXX Laboratories, Inc. provides diagnostic, detection, and information systems for veterinary, food, and water testing applications. The Company also operates an international network of veterinary reference laboratories. IDEXX offers its products to customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

IDEXX Laboratories (IDXX US)

IDEXX Laboratories Is Defying Global Economic Shocks—How Is It Thriving Amid Tariff Turbulence & Market Volatility?

IDEXX Laboratories reported its first-quarter 2025 financial results, revealing a mixed performance with notable areas of strength as well as...

Baptista Research

IDEXX: Pet Healthcare Could Be An Investor's Best Friend

IDEXX Laboratories is a global leader in veterinary diagnostics, and operates a highly recurring, subscription-like business model, with EBITDA...

Finimize Research

IDEXX Laboratories: Executing International Expansion To Capitalize On Its Competitive Edge Across Global Veterinary Markets!

IDEXX Laboratories, a global leader in veterinary diagnostics, software, and water quality products, closed out 2024 with a solid performance,...

Baptista Research

IDEXX: Leading the Humanization of Pet Care Through Diagnostics

Like most good comedy bit, it is funny probably because there is an element of truth to it. As a society, we are increasingly humanizing our pets.

MBI Deep Dives

IDEXX Labs: Will Its Enhanced Diagnostic Capabilities & Innovation Bring A Shift In The Competitive Dynamics? - Major Drivers

IDEXX Laboratories, a prominent player in the diagnostics and veterinary healthcare sector, demonstrated a mixed performance in its latest...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)